Company / Operating Cash Flow
ALNYLAM PHARMACEUTICALS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$524.1M
FY2025
5-year range
-$615.0M / $524.1M
FY2021-FY2025
Trend
+6405.1%
vs FY2024
Sector context
#29 of 216
Health Care
What the data says
Operating Cash Flow changed +6405% YoY in FY2025, a notable deviation from the 9-year average annual change of +696%.
Based on SEC 10-K filings.
$524M in FY2025. Top quartile in the Health Care sector.
Improved from $104M to $524M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 216This company $524.1M Sector average $659.0M
▼
-20.5% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 6405.1% year-over-year.
- Ranks #29 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $524.1M | +6405.1% |
| FY2024 | -$8.3M | -108.0% |
| FY2023 | $104.2M | +116.9% |
| FY2022 | -$615.0M | -120.9% |
| FY2021 | -$278.4M | +50.5% |
| FY2020 | -$562.6M | -47.0% |
| FY2019 | -$382.8M | -24.4% |
| FY2018 | -$307.7M | +19.6% |
| FY2017 | -$382.8M | -24.4% |
| FY2016 | -$307.7M | -62.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026